Vikram Sinha

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

Christian Wagner, Ping Zhao, Y. Pan et al. · CPT Pharmacometrics & Systems Pharmacology · 2015 · 268 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 212 citations

Medicine, Oncology, Pharmacology +16

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Michael A. Carducci, Luna Musib, Merrill S. Kies et al. · Journal of Clinical Oncology · 2006 · 173 citations

Pharmacy, Oncology, Pharmacology +15

In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective

Valeria Chu, Heidi J. Einolf, Raymond Evers et al. · Drug Metabolism and Disposition · 2009 · 161 citations

Medicine, Pharmacokinetics, Pharmacology +17

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Mallika Lala, Tommy Li, Dinesh P. de Alwis et al. · European Journal of Cancer · 2020 · 159 citations

Pharmacy, Oncology, Pharmacokinetics +12